- Home
- XNET vs AVTX Comparison
XNET vs AVTX Comparison
Compare XNET & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNET | AVTX |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.4M | 328.4M |
| IPO Year | 2011 | 2015 |
Fundamental Metrics
Financial Performance| Metric | XNET | AVTX |
|---|---|---|
| Price | $4.96 | $13.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $40.57 |
| AVG Volume (30 Days) | 236.3K | ★ 2.5M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.29 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $4.02 | $4.06 |
| 52 Week High | $11.03 | $24.27 |
Technical Indicators
Market Signals| Indicator | XNET | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.53 | 36.60 |
| Support Level | N/A | $13.22 |
| Resistance Level | $6.12 | $15.63 |
| Average True Range (ATR) | 0.30 | 1.15 |
| MACD | -0.08 | -0.48 |
| Stochastic Oscillator | 0.85 | 3.74 |
Price Performance
Historical ComparisonAbout XNET Xunlei Limited
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.